Latest News & Features
%20at%20IP%20firm%20Mewburn%20Ellis.jpg/r%5Bwidth%5D=1280&r%5Bheight%5D=720/4e51dc50-031c-11ef-9bd6-93566cb3a995-Katherine%20Collins%2C%20Associate%2C%20Patent%20Attorney%20(Life%20Sciences)%20at%20IP%20firm%20Mewburn%20Ellis.webp)
Biotechnology
Improving patient access is a UN goal but for companies transitioning from trials to full-scale production, IP is essential, explains Katherine Collins of Mewburn Ellis. 25 April 2024
Biotechnology
UK High Court invalidates two patents due to “overwhelming evidence” supplied by defendant | Biotech firm files same claims in Netherlands division of UPC on same day. 25 April 2024
Biotechnology
Vanda denied opportunity to revive patents for its sleep-disorder drug in dispute against Teva | Decision also rejects revisiting the 2007 case, KSR International v Teleflex, concerning the issue of obviousness in patent claims. 23 April 2024
Biotechnology
Opposition Division upholds patent challenged by 'straw men' | Dutch biotech has seen off challenges to patents in Europe and Japan. 23 April 2024
Medtech
Medtech company moved more than $1 billion in income from its US operations to a Caribbean island | New twist in long-running transfer pricing dispute between company and the IRS over ‘arm's-length’ royalty owed under intercompany licences. 18 April 2024
Biotechnology
As artificial intelligence creates a complex legal landscape for healthcare and medtech, Janine Swarbrick of HGF explores two case studies that shed light on how to claim an AI invention. 18 April 2024
Careers
Ex-head of Kramer Levin life sciences practice leaves for new firm | 20 years of experience includes numerous multi-billion dollar cases for some of the world’s best-selling drugs. 16 April 2024
Big Pharma
Judges determine six claims of Novarad’s AR patent to be unpatentable but uphold a further claim | Decision follows unsuccessful challenge by Medivis to another Novarad patent in March. 16 April 2024
Biotechnology
A US District Court has granted a motion to stay the company’s lawsuit against Pfizer and BioNTech | Decision pauses proceedings until two inter partes review proceedings are resolved. 16 April 2024
Big Pharma
Endo and its subsidiary have challenged the FDA's approval of an application by BPI Labs and Belcher Pharmaceuticals | Dispute argues the FDA undermined regulatory frameworks and patent protection. 11 April 2024